FDA orders vision-loss risk warning for GLP-1 drugs
publishers 48articles 50first reported 9 Nov, 16:45 UTCdeveloping since 9 Nov · 7 editions
The U.S. Food and Drug Administration has directed manufacturers of GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to add warnings about a potential increased risk of a rare eye condition that can cause permanent vision loss.
The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the optic nerve is reduced. It can cause sudden, painless loss of vision, usually in one eye. The FDA advised health care providers to consider discontinuing GLP-1 treatment when symptoms develop unless the benefits clearly outweigh the risk. People who have previously had NAION face an increased risk, the agency said.
The FDA said its decision followed a review of clinical trials, observational research and other evidence, including a 2024 study that prompted further investigation. An analysis of 126 randomized controlled trials found 6.4 NAION cases per 100,000 person-years among patients receiving GLP-1 drugs, compared with 3.8 cases among those given a placebo or a non-GLP-1 glucose-lowering treatment.
The evidence indicates a possible association but does not establish that the medications cause NAION. Novo Nordisk, which makes Ozempic and Wegovy, said available research has not demonstrated a causal relationship. The FDA nevertheless ordered manufacturers to include the potential risk in the warnings and precautions sections of the drugs’ labels.
HOW THIS STORY WAS MADE
Written from 8 articles, 2 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 42 h after the record first saw the story; the editor kept it as written.
- Publishers
- 48
- Source articles
- 50
- Given to the writer
- 8, 2 with the article's own text
- Independent newsrooms
- 8
- This version written
- 42 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and published it as written.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →